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Abstract Missense mutations and intronic mutations in the
gene for microtubule-associated protein tau cause frontotemporal
dementia and Parkinsonism linked to chromosome 17 (FTDP-
17). Most missense mutations have as likely primary effect a
reduced ability of tau to interact with microtubules. We report
here an additional effect of several missense mutations, namely
the stimulation of heparin-induced filament assembly of recom-
binant tau, despite the absence of any change in structure
indicated by circular dichroism. These findings indicate that
missense mutations in tau lead to frontotemporal dementia
through potentially multiple mechanisms.
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1. Introduction
Abundant ¢lamentous deposits made of hyperphosphory-
lated microtubule-associated protein tau constitute one of
the de¢ning neuropathological characteristics of Alzheimer’s
disease [1,2]. Similar deposits are found in a number of other
neurodegenerative diseases, such as Pick’s disease, progressive
supranuclear palsy and corticobasal degeneration. An autoso-
mal-dominantly inherited form of frontotemporal dementia
and Parkinsonism (known as FTDP-17) is also characterised
by an abundant ¢lamentous tau pathology and is linked to
chromosome 17q21^22, the same region that contains the tau
gene [3,4]. Recent work describing a number of exonic and
intronic mutations in the tau gene has shown that the FTDP-
17 locus is the tau gene [5^15]. The known mutations are
either missense or deletion mutations in the coding region of
tau, or intronic mutations located close to the splice-donor
site of the intron following exon 10 of the tau gene.
In adult human brain, six tau isoforms are produced from a
single gene by alternative mRNA splicing [16^18]. They di¡er
from each other by the presence of 29- or 58-amino acid
inserts located in the amino-terminal half and a 31-amino
acid repeat located in the carboxy-terminal half. Inclusion
of the latter, which is encoded by exon 10 of the tau gene,
gives rise to the three tau isoforms with four repeats each; the
other three isoforms have three repeats each. The repeats and
some adjoining sequences constitute the microtubule-binding
domains of tau [19,20].
Most missense mutations lead to a reduced ability of tau to
interact with microtubules, thus probably setting in motion
the mechanisms that lead to the formation of tau ¢laments
[15,21^23]. By contrast, the primary e¡ect of the intronic mu-
tations and of some missense mutations in exon 10 is at the
RNA level [6,24]. Intronic mutations and at least one missense
mutation destabilise a stem-loop structure at the boundary
between exon 10 and the intron following exon 10, resulting
in a net overproduction of four-repeat tau isoforms [7,22]. In
addition, some of the mutations that destabilise the stem-loop
structure are predicted to increase binding of U1snRNA
[7,24].
Besides leading to a reduced ability of tau to interact with
microtubules or to increase alternative mRNA splicing of
exon 10, missense and deletion mutations in tau may have
additional e¡ects. The mutations are located in the microtu-
bule-binding repeat region of tau or close to it. It is well
established that this region of the tau molecule forms the
core of the paired helical ¢lament of Alzheimer’s disease
[25^27]. In the present study, we have determined the circular
dichroism (CD) spectra of puri¢ed recombinant four-repeat
wild-type and mutant human tau proteins. We also used a
previously described method for assembling synthetic tau ¢l-
aments [28^30], in order to determine the e¡ects of seven tau
mutations on ¢lament assembly. We show that the mutant
proteins investigated had CD spectra indistinguishable from
the CD spectrum of wild-type tau. By contrast, several muta-
tions produced a marked stimulatory e¡ect on the heparin-
induced ¢lament assembly of recombinant tau protein.
2. Materials and methods
2.1. Expression and puri¢cation of wild-type and mutant tau proteins
Site-directed mutagenesis was used to change G272 to valine, to
delete K280, to change P301 to either leucine or serine, S305 to aspar-
agine, V337 to methionine or R406 to tryptophan in the four-repeat
412-amino acid isoform of human tau (expressed from cDNA clone
htau46) (in the numbering of the 441 amino acid isoform of human
tau). The three-repeat 381-amino acid isoform of human tau (ex-
pressed from cDNA clone htau37) was used to change G272 to valine,
V337 to methionine or R406 to tryptophan (using the numbering of
the 441-amino acid isoform of human tau). Wild-type and mutant tau
proteins were expressed in Escherichia coli BL21(DE3), as described
[31]. Bacterial pellets were resuspended in 50 mM Tris-HCl, pH 7.4,
0.5 mM EDTA, 0.1 mM DTT, 0.1 mM PMSF and sonicated. Super-
natants were passed onto a DE cellulose column and the £ow-through
applied to a phosphocellulose column equilibrated in the same bu¡er.
The column was step-washed with NaCl, with tau protein eluting at
0.5 M NaCl. Following precipitation with 50% ammonium sulphate,
protein was dissolved in 50 mM MES, pH 6.25, 50 mM NaCl, 0.1 mM
DTT, 0.1 mM PMSF and applied to a Sephacryl S-200 column. Tau
protein peak fractions were then applied directly to a Mono S column
equilibrated in the same bu¡er and protein was eluted using a NaCl
gradient. Peak tau protein fractions were combined and concentrated
using an Amicon dia£o ultracentrifugation apparatus (PM30 mem-
brane), followed by dialysis against 40 mM HEPES, pH 7.4, 0.1 mM
DTT. All puri¢cation steps were monitored by SDS-PAGE. In some
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experiments, 10 Wg amounts of tau proteins were fractionated on an
Aquapore RP-300 7 Wm C8 column using a gradient of 0.1% TFA to
0.04% TFA/90% acetonitrile at a £ow rate of 0.5 ml/min. Peak detec-
tion was at 225 nm.
2.2. Circular dichroism spectroscopy
Wild-type and mutant four-repeat tau proteins were used at 0.2^0.4
mg/ml in phosphate-bu¡ered saline (PBS). Protein concentrations
were determined by quantitative amino acid analysis. Spectra were
collected on a Jobin Yvon CD6 spectrophotometer using a 1-mm
cell at 25‡C. Curve smoothing made use of algorithms provided by
the manufacturer.
2.3. Tau ¢lament assembly
Puri¢ed wild-type or mutant forms of the 381- and 412-amino acid
isoforms of human tau (3 mg/ml) were incubated in the absence or the
presence of various concentrations of heparin (100, 200 and 400 Wg/
ml; British Drug House) in 25 Wl of 30 mM MOPS, 1 mM 4-(2-
aminoethyl)benzenesulphonyl£uoride (AEBSF, Calbiochem), pH 7.4,
at 37‡C for 48 h, as described [28,30]. Aliquots were placed onto
carbon-coated 400-mesh grids and stained with 1% lithium phospho-
tungstate. Micrographs were recorded at a nominal magni¢cation of
U40 000 on a Philips model EM208S electron microscope. Each ¢la-
ment assembly experiment made use of newly prepared batches of
recombinant wild-type and mutant tau proteins that had been puri¢ed
in parallel. The numbers of separate experiments for each four-repeat
mutant were as follows: G272V (n = 3); vK280 (n = 3); P301L (n = 5);
P301S (n = 4); S305N (n = 3); V337M (n = 3); R406W (n = 4). They
were as follows for the three-repeat tau mutants: G272V (n = 2);
V337M (n = 2); R406W (n = 2).
3. Results
The CD spectrum of bacterially expressed recombinant tau
protein (412-amino acid isoform of human tau) showed no
evidence of signi¢cant secondary structure, in con¢rmation
of previous reports using native and recombinant tau proteins
[32,33]. The FTDP-17 mutants G272V, vK280, P301L, P301S,
S305N, V337M and R406W (Fig. 1) had CD spectra that were
indistinguishable from those of the wild-type protein, compat-
ible with a ‘natively unfolded’ structure of the mutant tau
proteins and showing no evidence of any K-helical structure
(Fig. 2). Similarly, wild-type and mutant tau proteins had
identical elution patterns on reverse-phase HPLC, where
they all eluted at 33^34% acetonitrile.
The e¡ects of the FTDP-17 mutations G272V, vK280,
P301L, P301S, S305N, V337M and R406W on ¢lament as-
sembly of four-repeat tau were investigated in the absence and
the presence of the sulphated glycosaminoglycan, heparin (Ta-
ble 1, Fig. 3). In addition, the e¡ects of the G272V, V337M
and R406W mutations in the context of a three-repeat tau
isoform were also studied. Neither wild-type tau nor any of
the seven FTDP-17 tau mutants investigated formed ¢laments
in the absence of heparin over the 48-h incubation period. No
clear evidence of ¢lament formation was observed in the ab-
sence of heparin when the samples were left for up to 10 days
at 37‡C, with or without agitation. As observed before [28,30],
incubation of the four-repeat-containing tau isoform with
heparin gave predominantly straight ¢laments with a mor-
phology similar to the straight ¢laments from Alzheimer’s
disease brain. Incubation of the three-repeat-containing tau
isoform with heparin gave twisted ¢laments with a morphol-
ogy reminiscent of the paired helical ¢laments from Alzheim-
er’s disease brain, in con¢rmation of our previous ¢ndings
[28,30]. An additional class of ¢lament, appearing as thinner,
wavy structures, was also seen, as described [30]. Since the
relative numbers of each type of ¢lament (straight versus
wavy or twisted versus wavy) are strongly dependent on the
tau:heparin ratios [30], we used three di¡erent heparin con-
centrations in each experiment.
The relative e¡ects of the FTDP-17 mutations on heparin-
induced tau ¢lament assembly were assessed semi-quantita-
tively by electron microscopy (Table 1). A large stimulatory
e¡ect was observed with the P301L and P301S mutations
located in exon 10 (Fig. 3). No stimulatory e¡ect was seen
with the vK280 and S305N mutations which are also located
in exon 10 of the tau gene. This contrasted with the G272V
mutation in exon 9 that led to increased tau ¢lament assem-
bly, when compared with either wild-type three-repeat or
four-repeat tau protein (Fig. 3). The V337M mutation in
exon 12 gave a small increase in ¢lament numbers in the
three-repeat, but not the four-repeat tau isoform. The
R406W mutation in exon 13 gave similar numbers of ¢la-
ments to the wild-type protein, whether in the three-repeat
or the four-repeat tau isoform (Fig. 3).
4. Discussion
The discovery of tau gene mutations segregating with dis-
ease in FTDP-17 has shown that tau protein dysfunction
causes neurodegeneration. This is relevant, not only for
FTDP-17, but also for other diseases with a ¢lamentous tau
pathology, such as Alzheimer’s disease, Pick’s disease, pro-
gressive supranuclear palsy and corticobasal degeneration
[2]. Accordingly, there is great interest in the molecular mech-
Fig. 1. Schematic diagram of the 381- (three-repeat isoform) and
412-amino acid (four-repeat isoform) human tau proteins. Recombi-
nant proteins were expressed from cDNA clones htau37 and
htau46. The positions of the FTDP-17 mutations (G272V, vK280,
P301L, P301S, S305N, V337M and R406W) are indicated. Alterna-
tively spliced exons 2 and 10 are shown in white and the microtu-
bule-binding repeats are represented as black bars.
Table 1
Relative e¡ects of FTDP-17 mutations on heparin-induced assembly
of tau ¢laments
Number of ¢laments
Four-repeat tau isoform (TAU 46)
Wild-type +
G272V ++
vK280 +
P301L +++
P301S +++
S305N +
V337M +
R406W +
Three-repeat tau isoform (TAU 37)
Wild-type +
G272V ++
V337M ++
R406W +
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anisms by which tau mutations lead to frontotemporal de-
mentia.
Most missense mutations lead to a reduced ability of tau to
interact with microtubules, suggesting that this may be their
primary e¡ect [15,21^23]. Alternatively, intronic mutations
and some missense mutations lead to increased splicing of
exon 10, resulting in the overproduction of four-repeat-con-
taining tau isoforms [6,24]. This may result in an excess of
four-repeat tau over available binding sites on microtubules
and result in a reduced ability of excess four-repeat tau to
interact with microtubules. To date, all the mutations exam-
ined belong to one of these two groups. A reduced ability to
interact with microtubules has thus been proposed as a neces-
sary step for the hyperphosphorylation of tau and assembly of
tau into ¢laments [7,34].
Here we describe an additional e¡ect of some of the mis-
sense mutations in tau, namely a stimulatory e¡ect on hepa-
rin-induced ¢lament assembly of recombinant tau. Of the sev-
en mutations tested, by far the strongest e¡ects were seen with
the P301L and P301S mutations. Recombinant four-repeat
tau proteins with these mutations gave rise to a large increase
in the number of ¢laments when compared with the wild-type
protein. Proline residue 301 is located in exon 10 of the tau
gene and these mutations therefore only a¡ect four-repeat tau
isoforms. Two other mutations in exon 10, namely vK280 and
S305N, failed to increase heparin-induced tau ¢lament forma-
tion. The G272V mutation in exon 9 produced an increase in
tau ¢laments in both the three-repeat and four-repeat iso-
forms. A lesser e¡ect was seen for the V337M mutation in
exon 12 which had a small stimulatory e¡ect in the three-
repeat tau isoform. No stimulatory e¡ects were observed for
the R406W mutation in exon 13. A recent study using syn-
thetic peptides derived from each of the four microtubule-
binding domains of tau has shown increased heparin-induced
¢lament formation for the P301L mutation in repeat 2, but
not for the G272V mutation in repeat 1 [35].
Fig. 2. Circular dichroism spectra of wild-type and mutant four-repeat tau proteins (TAU 46). Wild-type tau and the tau mutants were mainly
random coil in phosphate-bu¡ered saline. The seven mutant proteins (G272V, vK280, P301L, P301S, S305N, V337M and R406W) were indis-
tinguishable from wild-type tau under these conditions.
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The e¡ects of tau mutations on ¢lament assembly were not
paralleled by changes in their CD spectra, where both wild-
type and mutant tau proteins showed a ‘natively unfolded’
structure. These ¢ndings are at variance with a recent report
describing an increase in K-helical content of recombinant tau
proteins with four of the missense mutations investigated here
[36]. The reasons for this discrepancy are unknown. However,
the fact that an overproduction of normal four-repeat tau
resulting from some mutations can lead to FTDP-17 indicates
that a signi¢cant change in the structure of tau is not neces-
sary for the development of pathology. Our CD spectra in-
dicate that the same is true of the missense and deletion mu-
tations of tau studied here.
The magnitude of the stimulatory e¡ects of tau mutations
on heparin-induced ¢lament assembly is comparable to their
relative inhibitory e¡ects on tau-promoted microtubule assem-
bly [15,21]. Thus, the P301L and P301S mutations produce a
strong inhibitory e¡ect on microtubule assembly, with inter-
Fig. 3. Representative ¢elds of ¢laments assembled from various wild-type and mutant tau proteins. A^E: Four-repeat tau (TAU 46). F^H:
Three-repeat tau (TAU 37). A: Wild-type; B: P301S; C: P301L; D: G272V; E: R406W; F: wild-type; G: G272V; H: V337M. Scale bar, 200
nm.
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mediate e¡ects of the G272V and V337M mutations and a
smaller e¡ect of the R406W mutation. Although we failed to
detect a stimulatory e¡ect of the R406W mutation on tau
¢lament assembly, we cannot exclude a small e¡ect that
may have gone undetected. The S305N mutation produces
no reduction in the ability of tau to promote microtubule
assembly and its primary e¡ect is at the RNA level [24]. It
had no detectable e¡ect on tau ¢lament assembly. The vK280
mutation appears to be an exception, since it has a strong
inhibitory e¡ect in microtubule assembly experiments [10],
without an obvious e¡ect on tau ¢lament assembly.
In view of the strong inhibitory e¡ects of the P301L and
P301S mutations on tau-promoted microtubule assembly
[15,21] and their stimulatory e¡ects on heparin-induced tau
¢lament assembly, one might expect these mutations to lead
to a more severe clinical phenotype than mutations with lesser
e¡ects, such as R406W. This is borne out to some extent, with
the P301S mutation leading to an early age of onset of disease
and a relatively short disease duration, with an extremely
severe tau pathology [15]. It contrasts with the R406W muta-
tion which produces a later age of onset and gives rise to a
more protracted disease course, with a less severe tau pathol-
ogy [37]. However, the P301L mutation leads to disease only
in mid-life, although the progression of disease can be rapid
and the tau pathology is severe [9,14,38,39].
Additional e¡ects, for example on the phosphorylation state
of tau, of the missense and deletion mutations in tau possibly
remain to be discovered. Where studied, pathological tau
from FTDP-17 brain is hyperphosphorylated, in a similar
manner to the pathological tau from Alzheimer’s disease brain
[4,34]. With the possible exception of the P301S mutation, the
known mutations in tau do not create additional phosphor-
ylation sites. Therefore, in most cases, hyperphosphorylation
of tau must be an event downstream of the primary e¡ects of
the tau mutations and may be a consequence of the partial
loss of function. It probably enhances the e¡ects of the mis-
sense and deletion mutations, since it is well established that
hyperphosphorylated tau is unable to bind to microtubules
[40,41]. Thus, an indirect e¡ect of the mutations on the phos-
phorylation of tau could contribute to disease. A number of
interactions between tau and several non-microtubule proteins
have been described [42^45]. It is possible that tau mutations
may interfere with some of these interactions.
In conclusion, the present study shows that some missense
mutations in tau lead to a marked stimulation of heparin-
induced formation of tau ¢laments. Together with the previ-
ously described e¡ects of these mutations on microtubule as-
sembly, it suggests that potentially multiple mechanisms
underlie the pathogenic e¡ects of the missense mutations in
tau.
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